
Quarterly report 2025-Q3
added 11-13-2025
Milestone Scientific EBITDA 2011-2026 | MLSS
Earnings before Interest, Taxes, Depreciation, and Amortization (EBITDA), is an often used measure of a company's profitability. Financial analysts use EBITDA for a number of purposes including calculating simple valuations of a firm, estimating cash flows, and assessing debt servicing capability. The uses for EBITDA in financial analysis are numerous, but in practice should be more restrained. While EBITDA has some useful applications, it should be used with caution, as the problems with EBITDA are abundant and can lead to a number of misguided conclusions.[1]
EBITDA is an important indicator for investors and analysts because it allows them to evaluate a company's operating profit without considering the impact of financial expenses, taxes, or non-cash depreciation and amortization. It provides better comparability between companies in different industries or with different tax conditions.
EBITDA is often used to assess a company's ability to generate cash flow and repay debts. It can also serve as a measure of a company's operational efficiency, as it shows how profitable the core business is, regardless of external factors such as interest or taxes.
However, it is important to note that EBITDA is not an official financial statement measure and can be defined and calculated differently by companies. Therefore, investors and analysts should exercise caution when using EBITDA as an evaluation tool and combine it with other financial metrics and information to get a more complete picture of a company's financial condition.
Annual EBITDA Milestone Scientific
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -6.72 M | -7.04 M | -8.76 M | -7.3 M | -7.41 M | -3.74 M | -5.58 M | -4.66 M | -6.35 M | -2.96 M | -694 K | 1.18 M | -425 K | -1.12 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 1.18 M | -8.76 M | -4.4 M |
Quarterly EBITDA Milestone Scientific
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -1.11 M | -1.47 M | -1.98 M | - | -1.46 M | -1.77 M | -1.45 M | - | -1.49 M | -2.26 M | -1.33 M | - | -2 M | -2.87 M | -1.9 M | - | -1.96 M | -2.86 M | -963 K | - | -1.46 M | -3.15 M | -1.57 M | - | -921 K | -1.08 M | -792 K | - | -4.2 M | -1.18 M | -1.74 M | - | -1.25 M | -1.52 M | -491 K | - | -1.5 M | -1.97 M | -921 K | - | -815 K | -1.4 M | -65.4 K | - | -150 K | 54.5 K | 333 K | - | 449 K | 1.47 M | 172 K | - | 66.1 K | -43.6 K | -228 K | - | -524 K | -251 K | -116 K |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 1.47 M | -4.2 M | -1.15 M |
References
- Brockman, C. M., & Russell, J. W. (2012). EBITDA: use it... or lose it?. International Journal of Business, Accounting and Finance, 6(2), 84-93.
EBITDA of other stocks in the Medical instruments industry
| Issuer | EBITDA | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Ekso Bionics Holdings
EKSO
|
-11.8 M | $ 10.0 | -2.25 % | $ 24.3 M | ||
|
Luminex Corporation
LMNX
|
72.9 M | - | - | $ 1.75 B | ||
|
Haemonetics Corporation
HAE
|
337 M | $ 65.33 | 2.22 % | $ 3.29 B | ||
|
Akers Biosciences, Inc.
AKER
|
-12.3 M | - | -9.52 % | $ 20.6 M | ||
|
AtriCure
ATRC
|
2.64 M | $ 31.54 | 1.96 % | $ 1.51 B | ||
|
Atrion Corporation
ATRI
|
37.7 K | - | - | $ 810 M | ||
|
iRhythm Technologies
IRTC
|
-36.7 M | $ 126.26 | -1.72 % | $ 4.04 B | ||
|
Isoray
ISR
|
-88.6 M | - | 0.03 % | $ 108 M | ||
|
The Cooper Companies
COO
|
1.06 B | $ 83.71 | -0.25 % | $ 16.7 B | ||
|
Alcon
ALC
|
580 M | $ 83.01 | -1.98 % | $ 40.4 B | ||
|
Repro Med Systems
KRMD
|
-9.4 M | $ 4.74 | -2.67 % | $ 216 M | ||
|
Antares Pharma, Inc.
ATRS
|
16.2 M | - | - | $ 955 M | ||
|
Cantel Medical Corp.
CMD
|
123 M | - | -1.18 % | $ 3.4 B | ||
|
CRH Medical Corporation
CRHM
|
33.9 M | - | - | $ 282 M | ||
|
LeMaitre Vascular
LMAT
|
78.3 M | $ 107.3 | -0.09 % | $ 2.43 B | ||
|
Hill-Rom Holdings, Inc.
HRC
|
518 M | - | -0.05 % | $ 10.3 B | ||
|
Masimo Corporation
MASI
|
-164 M | $ 175.37 | -0.02 % | $ 9.35 B | ||
|
Microbot Medical
MBOT
|
-9.75 M | $ 2.38 | -3.83 % | $ 24.3 M | ||
|
Baxter International
BAX
|
673 M | $ 19.09 | -3.07 % | $ 9.79 B | ||
|
Varian Medical Systems, Inc.
VAR
|
60 M | - | -0.02 % | $ 16.3 B | ||
|
Glaukos Corporation
GKOS
|
-95 M | $ 117.65 | -2.97 % | $ 5.7 B | ||
|
Predictive Oncology
POAI
|
-10.8 M | - | - | $ 31.1 M | ||
|
Harvard Bioscience
HBIO
|
3.37 M | $ 0.57 | -4.3 % | $ 24.2 M | ||
|
Becton, Dickinson and Company
BDX
|
5.04 B | $ 174.29 | -1.26 % | $ 50.1 B | ||
|
ResMed
RMD
|
1.16 B | $ 257.6 | 0.03 % | $ 37.6 B | ||
|
Retractable Technologies
RVP
|
-13.5 M | $ 0.69 | 4.5 % | $ 20.7 M | ||
|
AngioDynamics
ANGO
|
-14.2 M | $ 11.08 | -2.46 % | $ 453 M | ||
|
BioLife Solutions
BLFS
|
-1.97 M | $ 20.25 | -10.08 % | $ 933 M | ||
|
electroCore
ECOR
|
-18.3 M | $ 7.74 | -0.39 % | $ 42.7 K | ||
|
Envista Holdings Corporation
NVST
|
332 M | $ 28.66 | -2.65 % | $ 4.81 B | ||
|
Pulse Biosciences
PLSE
|
-76.5 M | $ 18.1 | -3.98 % | $ 1.22 B | ||
|
ICU Medical
ICUI
|
244 M | $ 142.63 | -2.97 % | $ 3.51 B | ||
|
InfuSystem Holdings
INFU
|
15 M | $ 9.21 | -1.07 % | $ 190 M | ||
|
Intuitive Surgical
ISRG
|
3.55 B | $ 496.56 | 0.06 % | $ 177 B | ||
|
Repligen Corporation
RGEN
|
116 M | $ 123.37 | -1.28 % | $ 6.87 M | ||
|
Merit Medical Systems
MMSI
|
308 M | $ 75.03 | -1.93 % | $ 4.44 B | ||
|
STAAR Surgical Company
STAA
|
-83.4 M | $ 18.98 | -0.39 % | $ 932 M | ||
|
Nephros
NEPH
|
-1.38 M | $ 4.0 | -1.96 % | $ 41.5 M | ||
|
NeuroMetrix
NURO
|
-8.69 M | - | 5.05 % | $ 9.02 M | ||
|
STERIS plc
STE
|
1.34 B | $ 243.28 | -1.79 % | $ 24 B | ||
|
OraSure Technologies
OSUR
|
-17.4 M | $ 2.99 | 1.01 % | $ 223 M | ||
|
Pro-Dex
PDEX
|
11.9 M | $ 47.48 | 2.93 % | $ 156 M | ||
|
Teleflex Incorporated
TFX
|
192 M | $ 121.73 | -0.88 % | $ 5.43 B | ||
|
Stereotaxis
STXS
|
-21.2 M | $ 2.17 | -2.48 % | $ 175 M | ||
|
Utah Medical Products
UTMD
|
17.4 M | $ 66.91 | -0.27 % | $ 243 M | ||
|
West Pharmaceutical Services
WST
|
756 M | $ 250.69 | -0.21 % | $ 18.1 B | ||
|
DENTSPLY SIRONA
XRAY
|
-70 M | $ 13.36 | -6.67 % | $ 2.66 B |